| scholarly article | Q13442814 |
| P50 | author | Emmanouil Sinakos | Q87908806 |
| Kris V. Kowdley | Q110296712 | ||
| P2093 | author name string | Hanns-Ulrich Marschall | |
| Keith Lindor | |||
| Jill Keach | |||
| Alex Befeler | |||
| P2860 | cites work | High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | Q24655731 |
| Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria | Q28328085 | ||
| Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration | Q28334026 | ||
| Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. | Q34330984 | ||
| Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases | Q34657625 | ||
| Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. | Q35087943 | ||
| Clinical features and management of primary sclerosing cholangitis | Q37182946 | ||
| A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation | Q37383640 | ||
| Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid | Q37731218 | ||
| Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II. | Q40336115 | ||
| Pharmacology of ursodeoxycholic acid, an enterohepatic drug. | Q40571618 | ||
| Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. | Q42199158 | ||
| High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis | Q43618408 | ||
| A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis | Q43770466 | ||
| Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate | Q44111064 | ||
| Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles | Q44165186 | ||
| Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis | Q45045457 | ||
| Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans | Q46637413 | ||
| High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective | Q46722756 | ||
| High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study | Q46802343 | ||
| Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. | Q51226271 | ||
| Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage | Q68059860 | ||
| Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I | Q70398501 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine | Q72719820 | ||
| Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response | Q73011043 | ||
| Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
| Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver | Q73491970 | ||
| Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis | Q77225890 | ||
| Influence of cholestasis on absorption of ursodeoxycholic acid | Q77373443 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ascending cholangitis | Q603644 |
| primary sclerosing cholangitis | Q1058608 | ||
| sclerosing cholangitis | Q18554727 | ||
| P304 | page(s) | 197-203 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression | |
| P478 | volume | 52 |
| Q35778052 | A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. |
| Q26771816 | A review of the medical treatment of primary sclerosing cholangitis in the 21st century |
| Q38103631 | Autoimmune hepatitis in diverse ethnic populations and geographical regions |
| Q51643325 | Clinical trials and their translation in hepatology: past, present, and future. |
| Q26772310 | Combination antiretroviral studies for patients with primary biliary cirrhosis |
| Q35066561 | Current research on the treatment of primary sclerosing cholangitis |
| Q90603976 | Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients |
| Q44511582 | Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies |
| Q27003179 | Diagnosis and management of the overlap syndromes of autoimmune hepatitis |
| Q57073739 | Dietary Bile Salt Types Influence the Composition of Biliary Bile Acids and Gut Microbiota in Grass Carp |
| Q90603645 | Diversification of host bile acids by members of the gut microbiota |
| Q41166877 | Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice |
| Q90722936 | Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities |
| Q37957967 | Evolving concepts in primary sclerosing cholangitis |
| Q37117971 | High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis |
| Q28237152 | High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis |
| Q33754301 | Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice |
| Q36197335 | Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. |
| Q38833243 | Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. |
| Q38554677 | Primary biliary cirrhosis: safety and benefits of established and emerging therapies |
| Q56442936 | Primary sclerosing cholangitis |
| Q85407194 | Primary sclerosing cholangitis and bile acids |
| Q46933007 | Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis |
| Q34464043 | Recent advances in the development of farnesoid X receptor agonists |
| Q38019989 | Recent insights in primary sclerosing cholangitis |
| Q42326059 | Specific bile acids inhibit hepatic fatty acid uptake in mice |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q37866339 | Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis |
| Q35917819 | The features of mucosa-associated microbiota in primary sclerosing cholangitis |
| Q35535485 | The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. |
| Q38037392 | The overlap syndromes of autoimmune hepatitis |
| Q37452047 | The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid |
| Q38058982 | Treatment of NASH with ursodeoxycholic acid: pro. |
| Q24567496 | Update on inflammatory bowel disease in patients with primary sclerosing cholangitis |
| Q48190174 | Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice |
| Q90604249 | Ursodeoxycholic acid (UDCA) mitigates the host inflammatory response during Clostridioides difficile infection by altering gut bile acids |
| Q37919924 | Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. |
| Q39170726 | Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. |
| Q89677698 | Ursodeoxycholic acid use is associated with significant risk of morbidity and mortality in infants with cholestasis: A strobe compliant study |
| Q38125078 | Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis |
Search more.